vs
MESA LABORATORIES INC（MLAB）与SYPRIS SOLUTIONS INC（SYPR）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是SYPRIS SOLUTIONS INC的2.2倍（$65.1M vs $30.3M），MESA LABORATORIES INC净利率更高（5.6% vs -12.9%，领先18.5%），MESA LABORATORIES INC同比增速更快（3.6% vs -9.5%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $-1.5M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -7.7%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
SYPRIS SOLUTIONS INC是美国的工程制造服务商，面向航空航天、国防、汽车、商用工业领域，提供定制化制造、性能测试及增值工程支持服务，满足全球企业客户关键任务系统及部件的相关需求。
MLAB vs SYPR — 直观对比
营收规模更大
MLAB
是对方的2.2倍
$30.3M
营收增速更快
MLAB
高出13.1%
-9.5%
净利率更高
MLAB
高出18.5%
-12.9%
自由现金流更多
MLAB
多$19.5M
$-1.5M
两年增速更快
MLAB
近两年复合增速
-7.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $30.3M |
| 净利润 | $3.6M | $-3.9M |
| 毛利率 | 64.2% | 4.6% |
| 营业利润率 | 12.2% | -10.9% |
| 净利率 | 5.6% | -12.9% |
| 营收同比 | 3.6% | -9.5% |
| 净利润同比 | 316.6% | -2992.6% |
| 每股收益（稀释后） | $0.65 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABSYPR
| Q4 25 | $65.1M | $30.3M | ||
| Q3 25 | $60.7M | $28.7M | ||
| Q2 25 | $59.5M | $31.4M | ||
| Q1 25 | $62.1M | $29.5M | ||
| Q4 24 | $62.8M | $33.4M | ||
| Q3 24 | $57.8M | $35.7M | ||
| Q2 24 | $58.2M | $35.5M | ||
| Q1 24 | $58.9M | $35.6M |
净利润MLABSYPR
| Q4 25 | $3.6M | $-3.9M | ||
| Q3 25 | $2.5M | $517.0K | ||
| Q2 25 | $4.7M | $-2.1M | ||
| Q1 25 | $-7.1M | $-899.0K | ||
| Q4 24 | $-1.7M | $135.0K | ||
| Q3 24 | $3.4M | $390.0K | ||
| Q2 24 | $3.4M | $16.0K | ||
| Q1 24 | $-254.6M | $-2.2M |
毛利率MLABSYPR
| Q4 25 | 64.2% | 4.6% | ||
| Q3 25 | 61.5% | 7.2% | ||
| Q2 25 | 62.0% | 8.2% | ||
| Q1 25 | 61.8% | 11.4% | ||
| Q4 24 | 63.3% | 16.1% | ||
| Q3 24 | 61.3% | 16.8% | ||
| Q2 24 | 64.0% | 15.9% | ||
| Q1 24 | 62.1% | 8.1% |
营业利润率MLABSYPR
| Q4 25 | 12.2% | -10.9% | ||
| Q3 25 | 7.8% | -6.1% | ||
| Q2 25 | 5.1% | -4.6% | ||
| Q1 25 | 2.4% | -0.4% | ||
| Q4 24 | 9.2% | 3.9% | ||
| Q3 24 | 6.1% | 4.8% | ||
| Q2 24 | 9.6% | 3.6% | ||
| Q1 24 | -460.6% | -3.9% |
净利率MLABSYPR
| Q4 25 | 5.6% | -12.9% | ||
| Q3 25 | 4.1% | 1.8% | ||
| Q2 25 | 8.0% | -6.5% | ||
| Q1 25 | -11.4% | -3.0% | ||
| Q4 24 | -2.7% | 0.4% | ||
| Q3 24 | 5.9% | 1.1% | ||
| Q2 24 | 5.8% | 0.0% | ||
| Q1 24 | -432.2% | -6.2% |
每股收益（稀释后）MLABSYPR
| Q4 25 | $0.65 | $-0.17 | ||
| Q3 25 | $0.45 | $0.02 | ||
| Q2 25 | $0.85 | $-0.09 | ||
| Q1 25 | $-1.30 | $-0.04 | ||
| Q4 24 | $-0.31 | $0.00 | ||
| Q3 24 | $0.63 | $0.02 | ||
| Q2 24 | $0.62 | $0.00 | ||
| Q1 24 | $-47.26 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | — |
| 总债务越低越好 | $68.4M | — |
| 股东权益账面价值 | $186.7M | $17.8M |
| 总资产 | $434.8M | $107.8M |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABSYPR
| Q4 25 | $29.0M | — | ||
| Q3 25 | $20.4M | — | ||
| Q2 25 | $21.3M | — | ||
| Q1 25 | $27.3M | — | ||
| Q4 24 | $27.3M | — | ||
| Q3 24 | $24.3M | — | ||
| Q2 24 | $28.5M | — | ||
| Q1 24 | $28.2M | — |
总债务MLABSYPR
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABSYPR
| Q4 25 | $186.7M | $17.8M | ||
| Q3 25 | $178.5M | $20.0M | ||
| Q2 25 | $172.5M | $18.7M | ||
| Q1 25 | $159.8M | $19.0M | ||
| Q4 24 | $155.2M | $19.6M | ||
| Q3 24 | $161.5M | $18.2M | ||
| Q2 24 | $150.7M | $19.0M | ||
| Q1 24 | $145.4M | $20.8M |
总资产MLABSYPR
| Q4 25 | $434.8M | $107.8M | ||
| Q3 25 | $430.4M | $112.5M | ||
| Q2 25 | $435.7M | $105.8M | ||
| Q1 25 | $433.3M | $110.2M | ||
| Q4 24 | $433.3M | $119.4M | ||
| Q3 24 | $454.1M | $121.6M | ||
| Q2 24 | $440.4M | $124.2M | ||
| Q1 24 | $446.8M | $129.0M |
负债/权益比MLABSYPR
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $-1.1M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $-1.5M |
| 自由现金流率自由现金流/营收 | 27.7% | -5.0% |
| 资本支出强度资本支出/营收 | 1.1% | 1.3% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $-6.5M |
8季度趋势，按日历期对齐
经营现金流MLABSYPR
| Q4 25 | $18.8M | $-1.1M | ||
| Q3 25 | $8.2M | $-178.0K | ||
| Q2 25 | $1.9M | $1.1M | ||
| Q1 25 | $12.7M | $-5.5M | ||
| Q4 24 | $18.1M | $2.3M | ||
| Q3 24 | $5.3M | $-4.8M | ||
| Q2 24 | $10.7M | $6.2M | ||
| Q1 24 | $12.9M | $-1.7M |
自由现金流MLABSYPR
| Q4 25 | $18.0M | $-1.5M | ||
| Q3 25 | $7.1M | $-390.0K | ||
| Q2 25 | $884.0K | $941.0K | ||
| Q1 25 | $11.9M | $-5.5M | ||
| Q4 24 | $17.3M | $1.9M | ||
| Q3 24 | $3.5M | $-4.9M | ||
| Q2 24 | $9.9M | $6.0M | ||
| Q1 24 | $12.3M | $-2.0M |
自由现金流率MLABSYPR
| Q4 25 | 27.7% | -5.0% | ||
| Q3 25 | 11.7% | -1.4% | ||
| Q2 25 | 1.5% | 3.0% | ||
| Q1 25 | 19.2% | -18.8% | ||
| Q4 24 | 27.6% | 5.7% | ||
| Q3 24 | 6.0% | -13.8% | ||
| Q2 24 | 16.9% | 16.8% | ||
| Q1 24 | 21.0% | -5.7% |
资本支出强度MLABSYPR
| Q4 25 | 1.1% | 1.3% | ||
| Q3 25 | 1.8% | 0.7% | ||
| Q2 25 | 1.7% | 0.5% | ||
| Q1 25 | 1.2% | 0.0% | ||
| Q4 24 | 1.3% | 1.2% | ||
| Q3 24 | 3.1% | 0.4% | ||
| Q2 24 | 1.5% | 0.5% | ||
| Q1 24 | 0.9% | 0.9% |
现金转化率MLABSYPR
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | -0.34× | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | 1.54× | -12.21× | ||
| Q2 24 | 3.17× | 385.25× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
